Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | ACE | P12821 | 2/20 | 0.45 |
| ▸ | FFAR2 | O15552 | 8/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7196787 | 0.89 | POLB (0.46) | POLBGAARAB9AACEFFAR2 | |
| SCHEMBL7193369 | 0.88 | POLB (0.57) | POLBGAARAB9AACEFFAR2 | |
| SCHEMBL7192631 | 0.86 | POLB (0.42) | POLBGAARAB9AACEALDH1A1 | |
| SCHEMBL7196968 | 0.84 | POLB (0.53) | POLBGAARAB9AACEFFAR2 | |
| SCHEMBL7196929 | 0.80 | ALDH1A1 (0.40) | POLBGAARAB9AALDH1A1 | |
| SCHEMBL7193645 | 0.79 | POLB (0.51) | POLBGAARAB9AACEFFAR2 | |
| SCHEMBL7191146 | 0.77 | POLB (0.46) | POLBGAARAB9AFFAR2HTT | |
| SCHEMBL7197324 | 0.75 | POLB (0.42) | POLBGAARAB9AALDH1A1 | |
| SCHEMBL7192887 | 0.74 | POLB (0.44) | POLBGAARAB9AACEHTT | |
| SCHEMBL7188457 | 0.71 | POLB (0.40) | POLBGAARAB9AACEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030022923-A1 | Methods for treatment of sickle cell anemia | MEDINOX, INC. | 2003-01-30 | — | — | US | disclosed |
| EP-1173174-A4 | METHODS FOR TREATMENT OF SICKLE CELL ANEMIA | MEDINOX INC (US) | 2002-09-18 | — | — | EP | disclosed |
| US-6355661-B1 | STABILITY OF ALDEHYDES AND PROTECTED ALDEHYDES | MEDINOX, INC. | 2002-03-12 | — | — | US | disclosed |
| EP-1173174-A1 | METHODS FOR TREATMENT OF SICKLE CELL ANEMIA | Medinox, Inc. (US) | 2002-01-23 | — | — | EP | disclosed |
| US-6251927-B1 | TREATING SICKLE CELL ANEMIA USING PROTECTED FORMS OF ORGANIC ALDEHYDES | MEDINOX, INC. | 2001-06-26 | — | — | US | disclosed |
| WO-2000062777-A1 | METHODS FOR TREATMENT OF SICKLE CELL ANEMIA | MEDINOX, INC. (US) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022923-A1 | Methods for treatment of sickle cell anemia | SORD, HBG1, HBG2 | POLB 1455/4885GAA 73/4885RAB9A 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.